ergoline and Raynaud-Disease

ergoline has been researched along with Raynaud-Disease* in 3 studies

Trials

2 trial(s) available for ergoline and Raynaud-Disease

Article	Year
[Clinical trial of a new vasoactive drug F.I. 6714 administered intra-arterially in peripheral vascular diseases]. Minerva cardioangiologica, 1975, Volume: 23, Issue:2 Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Drug Evaluation; Ergolines; Humans; Injections, Intra-Arterial; Leg; Nicergoline; Raynaud Disease; Vasodilator Agents	1975
[Therapeutic action of nicergoline in the treatment of cerebrovascular and peripheral disorders]. Il Farmaco; edizione pratica, 1974, Volume: 29, Issue:9 Topics: Adult; Aged; Arteriosclerosis; Attention; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Headache; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Nicotinic Acids; Pain; Raynaud Disease	1974

Other Studies

1 other study(ies) available for ergoline and Raynaud-Disease

Article	Year
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. European journal of clinical pharmacology, 2012, Volume: 68, Issue:1 It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson's disease (PD) has not been studied.. Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD.. We performed a nested case-control study using the PHARMO Institute for Drug Outcome Research database. All patients issued at least one prescription for levodopa after the age of 55 years between 1994 and 2006 were initially identified. Cases were patients who were hospitalized for the first time after November 1997 for an ischemic event and were matched to as many as four controls. Exposure to dopamine agonists during the year preceding the index date was identified.. The study population consisted of 542 cases and 2,155 controls. The mean effect of dopamine agonist use 1 year prior to the index date on ischemic events requiring hospitalization is shown with 95% probability in the 0.95-1.49 range. Stratified results according to the type of dopamine agonist showed no risk differences between ergoline and nonergoline agonists.. This study does not support an association between dopamine agonist use and an increased risk of ischemic events requiring hospitalization. Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain Ischemia; Case-Control Studies; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Hospitalization; Humans; Ischemia; Levodopa; Male; Myocardial Ischemia; Netherlands; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Raynaud Disease; Severity of Illness Index	2012

Article

Year

Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.

European journal of clinical pharmacology, 2012, Volume: 68, Issue:1

It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson's disease (PD) has not been studied.. Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD.. We performed a nested case-control study using the PHARMO Institute for Drug Outcome Research database. All patients issued at least one prescription for levodopa after the age of 55 years between 1994 and 2006 were initially identified. Cases were patients who were hospitalized for the first time after November 1997 for an ischemic event and were matched to as many as four controls. Exposure to dopamine agonists during the year preceding the index date was identified.. The study population consisted of 542 cases and 2,155 controls. The mean effect of dopamine agonist use 1 year prior to the index date on ischemic events requiring hospitalization is shown with 95% probability in the 0.95-1.49 range. Stratified results according to the type of dopamine agonist showed no risk differences between ergoline and nonergoline agonists.. This study does not support an association between dopamine agonist use and an increased risk of ischemic events requiring hospitalization.

Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain Ischemia; Case-Control Studies; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Hospitalization; Humans; Ischemia; Levodopa; Male; Myocardial Ischemia; Netherlands; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Raynaud Disease; Severity of Illness Index

2012